Type 17 CD8+ T cells display enhanced antitumor immunity

Blood

Volumn 114, Issue 3, 2009, Pages 596-599

  Hinrichs, Christian S ^a   Kaiser, Andrew ^a   Paulos, Chrystal M ^a   Cassard, Lydie ^a   Sanchez Perez, Luis ^a   Heemskerk, Bianca ^b   Wrzesinski, Claudia ^a   Borman, Zachary A ^a   Muranski, Pawel ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17R ALPHA; KILLER CELL LECTIN LIKE RECEPTOR G1; UNCLASSIFIED DRUG; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 7 RECEPTOR, ALPHA CHAIN; INTERLEUKIN-7 RECEPTOR, ALPHA CHAIN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CD8[+] T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; IN VITRO STUDY; KILLER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL; TUMOR IMMUNITY; ANIMAL; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; METHODOLOGY; SECRETION; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RECEPTORS, INTERLEUKIN-7; RECEPTORS, NK CELL LECTIN-LIKE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70149106667     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-203935     Document Type: Article

References (24)

1. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-1270.
2. Heslop HE, Brenner MK. The clone ranger? Mol Ther. 2008;16:1520-1521.
3. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838-2845. (Pubitemid 350006936)
4. Coccoris M, de Witte MA, Schumacher TN. Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther. 2005;5:583-593. (Pubitemid 43009503)
5. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
6. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest. 2007;117:1204-1212. (Pubitemid 46718405)
7. Lizée G, Cantu MA, Hwu P. Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res. 2007;13:5250-5255.
8. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362-373.
9. Bronte V. Th17 and cancer: friends or foes? Blood. 2008;112:214.
10. Kondo T, Takata H, Matsuki F, Takiguchi M. Cutting edge: phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol. 2009;182:1794-1798.
11. Intlekofer AM, Banerjee A, Takemoto N, et al. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science. 2008;321:408-411. (Pubitemid 352029977)
12. Tajima M, Wakita D, Noguchi D, et al. IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells. J Exp Med. 2008;205:1019-1027. (Pubitemid 351679678)
13. Kryczek I, Wei S, Gong W, et al. Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol. 2008;181:5842-5846.
14. Liu S-J, Tsai J-P, Shen C-R, et al. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6. J Leukoc Biol. 2007;82:354-360.
15. Pearce EL, Mullen AC, Martins GA, et al. Control of effector CD8(+) T cell function by the transcription factor Eomesodermin. Science. 2003;302:1041-1043. (Pubitemid 37386196)
16. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569-580.
17. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1616-1626.
18. Hinrichs CS, Spolski R, Paulos CM, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008;111:5326-5333.
19. Spolski R, Kim H-P, Zhu W, Levy DE, Leonard WJ. IL-21 mediates suppressive effects via its induction of IL-10. J Immunol. 2009;182:2859-2867.
20. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.
21. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-957. (Pubitemid 47300009)
22. Hinrichs CS, Gattinoni L, Restifo NP. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol. 2006;18:363-370.
23. Intlekofer AM, Takemoto N, Wherry EJ, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol. 2005;6:1236-1244. (Pubitemid 43045635)
24. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor ROR[gamma]t directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121-1133. (Pubitemid 44380299)